Cargando…

Immune-Related Uncommon Adverse Events in Patients with Cancer Treated with Immunotherapy

Immunotherapy has dramatically changed the therapeutic landscape of oncology, and has become standard of care in multiple cancer types in front or late lines of therapy, with some longstanding responses and outstanding results. Notwithstanding, its use has brought a totally unique spectrum of advers...

Descripción completa

Detalles Bibliográficos
Autores principales: Albarrán-Artahona, Víctor, Laguna, Juan-Carlos, Gorría, Teresa, Torres-Jiménez, Javier, Pascal, Mariona, Mezquita, Laura
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9498261/
https://www.ncbi.nlm.nih.gov/pubmed/36140493
http://dx.doi.org/10.3390/diagnostics12092091
_version_ 1784794714403241984
author Albarrán-Artahona, Víctor
Laguna, Juan-Carlos
Gorría, Teresa
Torres-Jiménez, Javier
Pascal, Mariona
Mezquita, Laura
author_facet Albarrán-Artahona, Víctor
Laguna, Juan-Carlos
Gorría, Teresa
Torres-Jiménez, Javier
Pascal, Mariona
Mezquita, Laura
author_sort Albarrán-Artahona, Víctor
collection PubMed
description Immunotherapy has dramatically changed the therapeutic landscape of oncology, and has become standard of care in multiple cancer types in front or late lines of therapy, with some longstanding responses and outstanding results. Notwithstanding, its use has brought a totally unique spectrum of adverse events, characterized by a myriad of diverse manifestations affecting nearly every organ and system of the body, including the endocrine, nervous, cardiac, respiratory and gastrointestinal systems. Uncommon adverse events, defined as those occurring in less than 1% of patients, comprise an even more heterogeneous group of diseases that are being seen more recurrently as the use of immune check-point inhibitors increases and indications spread in different tumor types and stages. Here, we comprehensively review some uncommon, but exceedingly important, immune-related adverse events, with special emphasis in the clinical approach and diagnostic workup, aiming to reunite the evidence published previously, allowing an increase in awareness and knowledge from all specialists implicated in the diagnosis, treatment, and care of cancer patients treated with immunotherapy.
format Online
Article
Text
id pubmed-9498261
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-94982612022-09-23 Immune-Related Uncommon Adverse Events in Patients with Cancer Treated with Immunotherapy Albarrán-Artahona, Víctor Laguna, Juan-Carlos Gorría, Teresa Torres-Jiménez, Javier Pascal, Mariona Mezquita, Laura Diagnostics (Basel) Review Immunotherapy has dramatically changed the therapeutic landscape of oncology, and has become standard of care in multiple cancer types in front or late lines of therapy, with some longstanding responses and outstanding results. Notwithstanding, its use has brought a totally unique spectrum of adverse events, characterized by a myriad of diverse manifestations affecting nearly every organ and system of the body, including the endocrine, nervous, cardiac, respiratory and gastrointestinal systems. Uncommon adverse events, defined as those occurring in less than 1% of patients, comprise an even more heterogeneous group of diseases that are being seen more recurrently as the use of immune check-point inhibitors increases and indications spread in different tumor types and stages. Here, we comprehensively review some uncommon, but exceedingly important, immune-related adverse events, with special emphasis in the clinical approach and diagnostic workup, aiming to reunite the evidence published previously, allowing an increase in awareness and knowledge from all specialists implicated in the diagnosis, treatment, and care of cancer patients treated with immunotherapy. MDPI 2022-08-29 /pmc/articles/PMC9498261/ /pubmed/36140493 http://dx.doi.org/10.3390/diagnostics12092091 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Albarrán-Artahona, Víctor
Laguna, Juan-Carlos
Gorría, Teresa
Torres-Jiménez, Javier
Pascal, Mariona
Mezquita, Laura
Immune-Related Uncommon Adverse Events in Patients with Cancer Treated with Immunotherapy
title Immune-Related Uncommon Adverse Events in Patients with Cancer Treated with Immunotherapy
title_full Immune-Related Uncommon Adverse Events in Patients with Cancer Treated with Immunotherapy
title_fullStr Immune-Related Uncommon Adverse Events in Patients with Cancer Treated with Immunotherapy
title_full_unstemmed Immune-Related Uncommon Adverse Events in Patients with Cancer Treated with Immunotherapy
title_short Immune-Related Uncommon Adverse Events in Patients with Cancer Treated with Immunotherapy
title_sort immune-related uncommon adverse events in patients with cancer treated with immunotherapy
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9498261/
https://www.ncbi.nlm.nih.gov/pubmed/36140493
http://dx.doi.org/10.3390/diagnostics12092091
work_keys_str_mv AT albarranartahonavictor immunerelateduncommonadverseeventsinpatientswithcancertreatedwithimmunotherapy
AT lagunajuancarlos immunerelateduncommonadverseeventsinpatientswithcancertreatedwithimmunotherapy
AT gorriateresa immunerelateduncommonadverseeventsinpatientswithcancertreatedwithimmunotherapy
AT torresjimenezjavier immunerelateduncommonadverseeventsinpatientswithcancertreatedwithimmunotherapy
AT pascalmariona immunerelateduncommonadverseeventsinpatientswithcancertreatedwithimmunotherapy
AT mezquitalaura immunerelateduncommonadverseeventsinpatientswithcancertreatedwithimmunotherapy